Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 05, 2015 4:39 AM ET

Healthcare Equipment and Supplies

Company Overview of bioLytical Laboratories Inc.

Company Overview

bioLytical Laboratories Inc. develops and manufactures diagnostic products. It provides INSTI, a HIV-1/HIV-2 rapid antibody test used for the detection of antibodies to human immunodeficiency virus type 1 in human whole blood, serum, or plasma. The company sells its products through distributors in Canada and India. bioLytical Laboratories Inc. was founded in 2002 and is based in Richmond, Canada.

1108 - 13351 Commerce Parkway

Richmond, BC V6V 2X7

Canada

Founded in 2002

Phone:

604-204-6784

Fax:

604-244-8399

Key Executives for bioLytical Laboratories Inc.

Chief Financial Officer
Chief Technical Officer and Vice President
Executive Director
Director of Automation and Materials
Director of Regulatory Affairs
Compensation as of Fiscal Year 2015.

bioLytical Laboratories Inc. Key Developments

bioLytical Laboratories Inc.'s INSTI HIV Test Detects gp41 Specific IgM Antibodies

bioLytical Laboratories Inc. announce its study 'Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its affinity for HIV gp41 IgM antibodies has been published in the Journal of Clinical Virology. This study highlights INSTI's ability to detect early HIV infection. BioLytical researchers presented their findings at the 8th annual International AIDS Society Conference, which highlighted early HIV detection using INSTI HIV-1/HIV-2 Antibody Test. The study demonstrated that both recombinant gp41 antigen and protein-A in the HIV screening assay have affinity to human IgM. When IgM was removed from early seroconversion samples that were once reactive with INSTI, the results were non-reactive or barely reactive. The study concluded that INSTI can detect anti-HIV-1 IgM antibodies, which enhances its utility in early HIV diagnosis. Early detection provides significant advantage in the fight against HIV/AIDS. INSTI HIV-1/HIV-2 Antibody Test's ability to detect early HIV antibodies is key to providing earlier diagnosis leading to earlier treatment.

bioLytical Laboratories Develops 60-Second Ebola Testing Kit

bioLytical Laboratories has successfully developed a pre-clinical prototype diagnostic test for the rapid detection of antibodies to the Ebola Zaire strain responsible for the current outbreak in West Africa. The prototype is based upon the company's proven, accurate, and highly accepted INSTI rapid test platform, which is capable of providing results in as little as 60 seconds.

Similar Private Companies By Industry

Company Name Region
Andromed Inc. Americas
Stellate Systems, Inc. Americas
Dumex Medical Surgical Products Ltd. Americas
SCIREQ Scientific Respiratory Equipment Inc. Americas
Optiway Technology Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact bioLytical Laboratories Inc., please visit www.biolytical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.